Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate .
LongeveronFebruary 18, 2021 GMT
MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Company’s Board of Directors.
Douglas Losordo, MD Dr. Losordo has worked in the biotech industry for over twenty years, most recently serving as Executive Vice President, Head of Research and Development and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage bio
(VERU) - Veru Raises $100M Via Equity At 10% Discount benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors
February 18, 2021 08:30 ET | Source: Longeveron Longeveron
MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE)
Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Company’s Board of Directors.
Douglas Losordo, MD
Dr. Losordo has worked in the biotech industry for over twenty years, most recently serving as Executive Vice President, Head of Research and Development and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage bioph
Edesa Biotech Reports Fiscal First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / February 16, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2020 and provided an update on its business.
Earlier this month, the company announced that it has been awarded a C$14 million reimbursement grant from the Canadian government. The funds will support the Phase 2 portion of an ongoing Phase 2/Phase 3 clinical study of Edesa s investigational drug, EB05, as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Should the antibody treatment demonstrate promising results at the Phase 2 readout, the company plans to continue with a pivotal Phase 3 study and enter negotiations for additional government funding. Last mont